$340 Million is the total value of JOHNSON & JOHNSON's 22 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | $75,725,000 | -9.6% | 3,379,064 | 0.0% | 22.28% | +4.2% | |
| LEGN | Legend Biotech Corporationads | $66,470,000 | -25.8% | 1,629,173 | 0.0% | 19.56% | -14.5% | |
| Sell | Procept BioRobotics Corporation | $35,818,000 | +7.6% | 863,908 | -15.2% | 10.54% | +23.9% | |
| CVRX | CVRx, Inc. | $32,614,000 | +55.2% | 3,495,575 | 0.0% | 9.60% | +78.8% | |
| MGTX | MeiraGTx Holdings plc | $24,377,000 | +11.1% | 2,898,550 | 0.0% | 7.17% | +28.0% | |
| PTGX | Protagonist Therapeutics Inc. | $20,647,000 | +6.6% | 2,449,183 | 0.0% | 6.08% | +22.8% | |
| XNCR | Xencor, Inc. | $19,435,000 | -5.1% | 748,062 | 0.0% | 5.72% | +9.3% | |
| Cue Health, Inc. | $16,702,000 | -5.9% | 5,548,864 | 0.0% | 4.92% | +8.4% | ||
| FUSN | Fusion Pharmaceuticals Inc. | $11,048,000 | +20.9% | 3,670,516 | 0.0% | 3.25% | +39.2% | |
| ACET | Adicet Bio, Inc. | $10,366,000 | -2.6% | 728,944 | 0.0% | 3.05% | +12.2% | |
| ARWR | Sell | Arrowhead Pharmaceuticals, Inc. | $8,183,000 | -81.6% | 247,598 | -80.4% | 2.41% | -78.8% |
| PNT | Point Biopharma Global Inc. | $7,730,000 | +13.5% | 1,000,000 | 0.0% | 2.28% | +30.7% | |
| VOR | Vor Biopharma, Inc. | $4,277,000 | -19.9% | 1,074,658 | 0.0% | 1.26% | -7.7% | |
| NNOX | Nano-X Imaging Ltd. | $2,207,000 | +1.5% | 192,429 | 0.0% | 0.65% | +16.9% | |
| ALDX | Aldeyra Therapeutics, Inc. | $2,108,000 | +33.8% | 394,834 | 0.0% | 0.62% | +54.2% | |
| SomaLogic, Inc. | $815,000 | -35.8% | 281,052 | 0.0% | 0.24% | -25.9% | ||
| PHGE | BiomX Inc. | $725,000 | -53.4% | 2,133,402 | 0.0% | 0.21% | -46.5% | |
| PHAS | PhaseBio Pharmaceuticals, Inc. | $283,000 | -70.6% | 1,607,044 | 0.0% | 0.08% | -66.3% | |
| TCON | Tracon Pharmaceuticals, Inc. | $140,000 | -16.7% | 84,003 | 0.0% | 0.04% | -4.7% | |
| SENS | Senseonics Holdings, Inc. | $72,000 | +28.6% | 54,621 | 0.0% | 0.02% | +50.0% | |
| GRAY | Graybug Vision, Inc. | $47,000 | -13.0% | 49,547 | 0.0% | 0.01% | 0.0% | |
| CBIO | Catalyst Biosciences, Inc. | $34,000 | -71.4% | 66,951 | 0.0% | 0.01% | -66.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.